Abstract
Olaparib is the first drug of a group of PARP inhibitors intervening in DNA repair mechanisms in the tumour cell. It has received registration for oral use as maintenance therapy in patients with platinum sensitive recurrent ovarian cancer and harbouring germinal or somatic mutation of BRCA1/2 genes.
It is characterised by low, well manageable toxicity.